IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Christopher C. Fraser, et al.

Application No.:   09/759,130   Group No.:

Filed: January 12, 2001   Examiner:

For: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

1. [X] This replies to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated June 26, 2002.

    [X] A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures including the Raw Sequence Listing Error Report is enclosed.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☑   deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

        37 C.F.R. SECTION 1.8(a)   **37 C.F.R. SECTION 1.10***

☑   with sufficient postage as first class mail.   ☐   as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

☐   transmitted by facsimile to the Patent and Trademark Office.

Signature _____
Sean Hunziker

Date: September 13, 2002

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

(Page 1 of 4)

IDENTIFICATION OF PERSON MAKING STATEMENT

2.   I, Jean M. Silveri, state the following:

ITEMS BEING SUBMITTED

3.   Submitted herewith is/are:

A.   (X)   "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.

B.   ( )   An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).

C.   (X)   A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.

D.   (X)   Executed Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney.

E.   ( )   Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computereadable copy(ies) from applicant's other application identified as follows:

In re application of: , et al
Application No.:   Group No.:
Filed: Examiner:
For:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form   "Sequence Identifier"

(other application)   (this application)

F.   [ ]   A statement that the content of each "Sequence Listing" submitted and each computer

readable copy are the same, as required in 37 C.F.R. Section 1.821(g).

( ) Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

G. [X] Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

( ) Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

EXTENSION OF TERM

5. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(a) [X] Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than small entity	Fee for small entity
[X] one month	$ 110.00	$ 55.00
( ) two months	$ 390.00	$ 195.00
( ) three months	$ 890.00	$ 445.00
( ) four months	$1,390.00	$ 695.00

Fee **$110.00**

If an additional extension of time is required, please consider this a petition therefor.

[ ] An extension for one month has already been secured, and the fee paid therefor of
$0.00   is deducted from the total fee due for the total months of extension
now requested.

Extension fee due with this request **$110.00**

OR

(b) [ ] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

6. [ ] Attached is a check in the sum of $_____ .

[X] Charge Account No. **501668**   the sum of   **$110.00**   .
A duplicate of this transmittal is attached.

FEE DEFICIENCY

8. [X] If any additional extension and/or fee is required, charge Account No. **501668**   .

September 13, 2002   MILLENNIUM PHARMACEUTICALS, INC.

By _____
Jean M. Silveri
Registration No. 39,030
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-679-7336
Facsimile - 617-551-8820

COPY

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/759,130	01/12/2001	Christopher C. Fraser	10147-66 (MPI2000-535OMNI

000570
AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.
ONE COMMERCE SQUARE
2005 MARKET STREET, SUITE 2200
PHILADELPHIA, PA 19103

CONFIRMATION NO. 2853
FORMALITIES LETTER

OC000000008352535

Date Mailed: 06/26/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

0360

MuM **COPY** BIOTECHNOLOGY
SYSTEMS·
BRANCH

@4726
83 803co

RAW SEQUENCE LISTING
ERROR REPORT

SEP 16 2002 PATENT & TRADEMARK OFFICE

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: ___ 09/759,130A

Source: ___ 01PE

Date Processed by STIC: ___ 10/4/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY
FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.
Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO).
Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:
http://www.uspto.gov/web/offices/pac/checker

OIPE

SEP 1 6 2002

PATENT & TRADEMARK OFFICE

Re-run

OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/759,130A

DATE: 10/04/2001
TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

Does Not Comply
Corrected Diskette Needed

3 <110> APPLICANT: MCCARTHY, Sean A
4   FRASER, Christopher C
5   SHARP, John D
6   BARNES, Thomas S
7   KIRST, Susan J
8   MACKAY, Charles R
9   MYERS, Paul S
10   LEIBY, Kevin R
11   WRIGHTON, Nicholas
12   GOODEARL, Andrew
13   HOLTZMAN, Douglas A
15 <120> TITLE OF INVENTION: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC,
16   DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES
18 <130> FILE REFERENCE: 210147.0066/66US
20 <140> CURRENT APPLICATION NUMBER: US/09/759,130A
21 <141> CURRENT FILING DATE: 2001-01-19
23 <150> PRIOR APPLICATION NUMBER: US 09/479,249
24 <151> PRIOR FILING DATE: 2000-01-07
26 <150> PRIOR APPLICATION NUMBER: US 09/559,497
27 <151> PRIOR FILING DATE: 2000-04-27
29 <150> PRIOR APPLICATION NUMBER: US 09/578,063
30 <151> PRIOR FILING DATE: 2000-05-24
32 <150> PRIOR APPLICATION NUMBER: US 09/333,159
33 <151> PRIOR FILING DATE: 1999-06-14
35 <150> PRIOR APPLICATION NUMBER: US 09/596,194
36 <151> PRIOR FILING DATE: 2000-07-14
38 <150> PRIOR APPLICATION NUMBER: US 09/342,364
39 <151> PRIOR FILING DATE: 1999-06-29
41 <150> PRIOR APPLICATION NUMBER: US 09/608,452
42 <151> PRIOR FILING DATE: 2000-06-30
44 <150> PRIOR APPLICATION NUMBER: US 09/393,996
45 <151> PRIOR FILING DATE: 1999-09-10
47 <150> PRIOR APPLICATION NUMBER: US 09/602,871
48 <151> PRIOR FILING DATE: 2000-06-23
50 <150> PRIOR APPLICATION NUMBER: US 09/420,707
51 <151> PRIOR FILING DATE: 1999-10-19
53 <160> NUMBER OF SEQ ID NOS: 460
55 <170> SOFTWARE: PatentIn Ver. 2.1

ERRORED SEQUENCES

216 <210> SEQ ID NO.: 3
217 <211> LENGTH: 1151   911 (p. 4)
218 <212> TYPE: PRT
219 <213> ORGANISM: Homo sapiens
221 <400> SEQUENCE: 3

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
222 Met His Gln Met Asn Ala Lys Met His Phe Arg Phe Val Phe Ala Leu
223  1                   5                   10                  15
225 Leu Ile Val Ser Phe Asn His Asp Val Leu Gly Lys Asn Leu Lys Tyr
226              20                  25                  30
228 Arg Ile Tyr Glu Glu Gln Arg Val Gly Ser Val Ile Ala Arg Leu Ser
229          35                  40                  45
231 Glu Asp Val Ala Asp Val Leu Leu Lys Leu Pro Asn Pro Ser Thr Val
232      50                  55                  60
234 Arg Phe Arg Ala Met Gln Arg Gly Asn Ser Pro Leu Leu Val Val Asn
235  65                  70                  75                  80
237 Glu Asp Asn Gly Glu Ile Ser Ile Gly Ala Thr Ile Asp Arg Glu Gln
238                  85                  90                  95
240 Thr Leu Pro Thr Glu His Leu Gln Leu Phe His Ile Glu Val Glu Val
241              100                 105                 110
243 Leu Asp Ile Asn Asp Asn Ser Pro Gln Phe Ser Arg Ser Leu Ile Pro
244              115                 120                 125
246 Ile Glu Ile Ser Glu Ser Ala Ala Val Gly Thr Arg Ile Pro Leu Asp
247      130                 135                 140
249 Ser Ala Phe Asp Pro Asp Val Gly Glu Asn Ser Leu His Thr Tyr Ser
250 145                 150                 155                 160
252 Leu Ser Ala Asn Asp Phe Phe Asn Ile Glu Val Arg Thr Arg Thr Asp
253              165                 170                 175
255 Glu Leu Lys Ser Ser Tyr Glu Leu Gln Leu Thr Ala Ser Asp Met Gly
256              180                 185                 190
258 Val Pro Gln Arg Ser Gly Ser Ser Ile Leu Lys Ile Ser Ile Ser Asp
259          195                 200                 205
261 Ser Asn Asp Asn Ser Pro Ala Phe Glu Gln Gln Ser Tyr Ile Ile Gln
262      210                 215                 220
264 Leu Leu Glu Asn Ser Pro Val Gly Thr Leu Leu Leu Asp Leu Asn Ala
265 225                 230                 235                 240
267 Thr Asp Pro Asp Glu Gly Ala Asn Gly Lys Ile Val Tyr Ser Phe Ser
268                  245                 250                 255
270 Ser His Val Ser Pro Lys Ile Met Glu Thr Phe Lys Ile Asp Ser Glu
271              260                 265                 270
273 Lys Ser Tyr Glu Ile Asp Val Gln Ala Gln Asp Leu Gly Pro Asn Ser
274          275                 280                 285
276 Ile Pro Ala His Cys Lys Ile Ile Ile Lys Val Val Asp Val Asn Asp
277      290                 295                 300
279 Asn Lys Pro Glu Ile Asn Ile Asn Leu Met Ser Pro Gly Lys Glu Glu
280 305                 310                 315                 320
282 Ile Ser Tyr Ile Phe Glu Gly Asp Pro Ile Asp Thr Phe Val Ala Leu
283              325                 330                 335
285 Val Arg Val Gln Asp Lys Asp Ser Gly Leu Asn Gly Glu Ile Val Cys
286          340                 345                 350
288 Asn Asn Tyr Leu Ile Leu Thr Asn Ala Thr Leu Asp Arg Glu Lys Arg
289          355                 360                 365
291 Ser Glu Tyr Ser Leu Thr Val Ile Ala Glu Asp Arg Gly Thr Pro Ser
292      370                 375                 380
294 Leu Ser Thr Val Lys His Phe Thr Val Gln Ile Asn Asp Ile Asn Asp
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
295 385                   390                   395               .   400
297 Asn Pro Pro His Phe Gln Arg Ser Arg Tyr Glu Phe Val Ile Ser Glu
298         .           405                   410                   415
300 Asn Asn Ser Pro Gly Ala Tyr Ile Thr Thr Val Thr Ala Thr Asp Pro
301             420                   425                   430
303 Phe Ile Leu Gly Ser Ser Ile Thr Thr Tyr Val Thr Ile Asp Pro Ser
304         435     ···               440         .           445
306 Asn Gly Ala Ile Tyr Ala Leu Arg Ile Phe Asp His Glu Glu Val Ser
307     ·450                   455                   460
309 Gln Ile Thr Phe Val Val Glu Ala Arg Asp Gly Gly Ser Pro Lys Gln
310 465       .           470           .       475                   480
312 Leu Val Ser Asn Thr Thr Val Val Leu Thr Ile Ile Asp Glu Asn Asp
313             485                   490                   495
315 Asn Val Pro Val Val Ile Gly Pro Ala Leu Arg Asn Asn Thr Ala Glu
316             500                   505                   510
318 Ile Thr Ile Pro Lys Gly Ala Glu Ser Gly Phe His Val Thr Arg Ile
319             515                   520                   525
321 Ala Ile Val Ala Gly Asn Glu Glu Asn Ile Phe Ile Ile Asp Pro Arg
322         530                   535                   540
324 Ser Cys Asp Ile His Thr Asn Val Ser Met Asp Ser Val Pro Tyr Thr
325 545                   550                   555                   560
327 Glu Trp Glu Leu Ser Val Ile Ile Gln Asp Lys Gly Asn Pro Gln Leu
328             .     565               570                   575
330 His Thr Lys Val Leu Leu Lys Cys Met Ile Phe Glu Tyr Ala Glu Ser
331             580                   585                   590
333 Val Thr Ser Thr Ala Met Thr Ser Val Ser Gln Ala Ser Leu Asp Val
334         .595                   600               ⁝   605
336 Leu Val Ile Met Val Leu Phe Ala Thr Arg Cys Asn Arg Glu Lys Lys
337         610                   615                   620
339 Asp Thr Arg Ser Tyr Asn Cys Arg Val Ala Glu Ser Thr Tyr Gln His
340 625                   630                   635                   640
342 His Pro Lys Arg Pro Ser Arg Gln Ile His Lys Gly Asp Ile Thr Leu
343             645                   650                   655
345 Val Pro Thr Ile Asn Gly Thr Leu Pro Ile Arg Ser His His Arg Ser
346             660                   665                   670
348 Ser Pro Ser Ser Ser Pro Thr Leu Glu Arg Gly Gln Met Gly Ser Arg
349             675                   680                   685
351 Ser Ser Asn His Val Pro Glu Asn Phe Ser Leu Glu Leu Thr His Ala
352         690         ⁝ ⁝   695                   700
354 Thr Pro Ala Val Glu Gln Val Ser Gln Leu Leu Ser Met Leu His Gln
355 705             ⁝ 710                   715                   720
357 Gly Gln Tyr Gln Pro Arg Pro Ser Phe Arg Gly Asn Lys Tyr Ser Arg
358         .           725                   730                   735
360 Ser Tyr Arg Tyr Ala Leu Gln Asp Met Asp Lys Phe Ser Leu Lys Asp
361             740                   745                   750
363 Ser Gly Arg Gly Asp Ser Glu Ala Gly Asp Ser Asp Tyr Asp Leu Gly
364             755         .       760                   765
366 Arg Asp Ser Pro Ile Asp Arg Leu Leu Gly Glu Gly Phe Ser Asp Leu
367         770                   775   .               780
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
369 Glu Glu Cys Arg Val Leu Gly His Ser Asp Gln Cys Trp Met Pro Pro
370 785                   790                 795               800
372 Leu Pro Ser Pro Ser Ser Asp Tyr Arg Ser Asn Met Phe Ile Pro Gly
373               805               810               815
375 Glu Glu Phe Pro Thr Gln Pro Gln Gln Gln His Pro His Gln Ser Leu
376               820               825               830
378 Glu Asp Asp Ala Gln Pro Ala Asp Ser Gly Glu Lys Lys Lys Ser Phe
379               835               840               845
381 Ser Thr Phe Gly Lys Asp Ser Pro Asn Asp Glu Asp Thr Gly Asp Thr
382       850               855               860
384 Val Asp Arg Ser Asn Ser Leu Glu Arg Arg Lys Gly Pro Leu Pro Ala
385 865               870               875               880
387 Glu Glu Ile Pro Glu Asn Tyr Glu Glu Asp Asp Phe Asp Asn Val Leu
388               885               890               895
390 Leu Val Ala Glu Ile Asn Lys Leu Leu Gln Asp Val Arg Gln Ser
E--> 391               900               905               910
```

```
1579 <210> SEQ ID NO: 38
1580 <211> LENGTH: 425 295 (p. 5)
1581 <212> TYPE: PRT
1582 <213> ORGANISM: Homo sapiens
1584 <400> SEQUENCE: 38
1585 Ala Thr Arg Cys Asn Arg Glu Lys Lys Asp Thr Arg Ser Tyr Asn Cys
1586  1               5               10               15
1588 Arg Val Ala Glu Ser Thr Tyr Gln His His Pro Lys Arg Pro Ser Arg
1589               20               25               30
1591 Gln Ile His Lys Gly Asp Ile Thr Leu Val Pro Thr Ile Asn Gly Thr
1592               35               40               45
1594 Leu Pro Ile Arg Ser His His Arg Ser Ser Pro Ser Ser Ser Pro Thr
1595       50               55               60
1597 Leu Glu Arg Gly Gln Met Gly Ser Arg Gln Ser His Asn Ser His Gln
1598  65               70               75               80
1600 Asn Phe Ser Leu Glu Leu Thr His Ala Thr Pro Ala Val Glu Val Ser
1601               85               90               95
1603 Gln Leu Leu Ser Met Leu His Gln Gly Gln Tyr Gln Pro Arg Pro Ser
1604               100               105               110
1606 Phe Arg Gly Asn Lys Tyr Ser Arg Ser Tyr Arg Tyr Ala Leu Gln Asp
1607               115               120               125
1609 Met Asp Lys Phe Ser Leu Lys Asp Ser Gly Arg Gly Asp Ser Glu Ala
1610       130               135               140
1612 Gly Asp Ser Asp Tyr Asp Leu Gly Arg Asp Ser Pro Ile Asp Arg Leu
1613 145               150               155               160
1615 Pro Ala Ala Met Arg Leu Cys Thr Glu Glu Cys Arg Val Leu Gly His
1616               165               170               175
1618 Ser Asp Gln Cys Trp Met Pro Pro Leu Pro Ser Pro Ser Ser Asp Tyr
1619               180               185               190
1621 Arg Ser Asn Met Phe Ile Pro Gly Glu Glu Phe Pro Thr Gln Pro Gln
1622               195               200               205
1624 Gln Gln His Pro His Gln Ser Leu Glu Asp Asp Ala Gln Pro Ala Asp
1625       210               215               220
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
1627 Ser Gly Glu Lys Lys Lys Ser Phe Ser Thr Phe Gly Lys Asp Ser Pro
1628 225             230             235             240
1630 Ser Glu Met Ser Ser Val Phe Gln Arg Leu Leu Pro Pro Ser Leu Asp
1631             245             250             255
1633 Thr Asn Cys Gly Pro Pro Leu Gly Thr His Ser Ser Val Gln Pro Ser
1634             260             265             270
1636 His Glu Leu Met Asp Ala Ser Glu Leu Val Ala Glu Ile Asn Lys Leu
1637             275             280             285
1639 Leu Gln Asp Val Arg Gln Ser
E--> 1640    290             295
1762 <210> SEQ ID NO: 42
1763 <211> LENGTH: (1183) 1135 (p.8)
1764 <212> TYPE: PRT
1765 <213> ORGANISM: Mus sp.
1767 <400> SEQUENCE: 42
1768 Met Met Leu Leu Leu Pro Phe Leu Leu Gly Leu Leu Gly Pro Gly Ser
1769   1             5               10              15
1771 Tyr Leu Phe Ile Ser Gly Asp Cys Gln Glu Val Ala Thr Val Met Val
1772             20              25              30
1774 Lys Phe Gln Val Thr Glu Glu Val Pro Ser Gly Thr Val Ile Gly Lys
1775             35              40              45
1777 Asp Ala Phe Gln Ile Leu Gln Leu Pro Gln Ala Leu Pro Val Gln Met
1778       50              55              60
1780 Asn Ser Glu Asp Gly Leu Leu Ser Thr Ser Ser Arg Leu Asp Arg Glu
1781  65              70              75              80
1783 Lys Leu Cys Arg Gln Glu Asp Pro Cys Leu Val Ser Phe Asp Val Leu
1784             85              90              95
1786 Ala Thr Gly Ala Ser Ala Leu Ile His Val Glu Ile Gln Val Leu Asp
1787             100             105             110
1789 Ile Asn Asp His Gln Pro Gln Phe Pro Lys Asp Glu Gln Glu Leu Glu
1790             115             120             125
1792 Ile Ser Glu Ser Ala Ser Leu His Thr Arg Ile Pro Leu Asp Arg Ala
1793       130             135             140
1795 Leu Asp Gln Asp Thr Gly Pro Asn Ser Leu Tyr Ser Tyr Ser Leu Ser
1796 145             150             155             160
1798 Pro Ser Glu His Phe Ala Leu Asp Val Ile Val Gly Pro Asp Glu Thr
1799             165             170             175
1801 Lys His Ala Glu Leu Val Val Val Lys Glu Leu Asp Arg Glu Leu His
1802             180             185             190
1804 Ser Tyr Phe Asp Leu Val Leu Thr Ala Tyr Asp Asn Gly Asn Pro Pro
1805             195             200             205
1807 Lys Ser Gly Ile Ser Val Val Lys Val Asn Val Leu Asp Ser Asn Asp
1808       210             215             220
1810 Asn Ser Pro Val Phe Ala Glu Ser Ser Leu Ala Leu Glu Ile Pro Glu
1811 225             230             235             240
1813 Asp Thr Val Pro Gly Thr Leu Leu Ile Asn Leu Thr Ala Thr Asp Pro
1814             245             250             255
1816 Asp Gln Gly Pro Asn Gly Glu Val Glu Phe Phe Phe Gly Lys His Val
1817             260             265             270
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
1819 Ser Pro Glu Val Met Asn Thr Phe Gly Ile Asp Ala Lys Thr Gly Gln
1820         275                     280                 285
1822 Ile Ile Leu Arg Gln Ala Leu Asp Tyr Glu Lys Asn Pro Ala Tyr Glu
1823         290                 295                 300
1825 Val Asp Val Gln Ala Arg Asp Leu Gly Pro Asn Ser Ile Pro Gly His
1826 305                     310                 315                 320
1828 Cys Lys Val Leu Ile Lys Val Leu Asp Val Asn Asp Asn Ala Pro Ser
1829             325                     330                 335
1831 Ile Leu Ile Thr Trp Ala Ser Gln Thr Ser Leu Val Ser Glu Asp Leu
1832             340                     345                 350
1834 Pro Arg Asp Ser Phe Ile Ala Leu Val Ser Ala Asn Asp Leu Asp Ser
1835         355                     360                 365
1837 Gly Asn Asn Gly Leu Val His Cys Trp Leu Asn Gln Glu Leu Gly His
1838         370                     375                 380
1840 Phe Arg Leu Lys Arg Thr Asn Gly Asn Thr Tyr Met Leu Leu Thr Asn
1841 385                 390                     395                 400
1843 Ala Thr Leu Asp Arg Glu Gln Trp Pro Ile Tyr Thr Leu Thr Val Phe
1844                 405                 410                 415
1846 Ala Gln Asp Gln Gly Pro Gln Pro Leu Ser Ala Glu Lys Glu Leu Gln
1847             420                 425                 430
1849 Ile Gln Val Ser Asp Val Asn Asp Asn Ala Pro Val Phe Glu Lys Ser
1850             435         ,           440                 445
1852 Arg Tyr Glu Val Ser Thr Trp Glu Asn Asn Pro Pro Ser Leu His Leu
1853         450                 455                 460
1855 Ile Thr Leu Lys Ala His Asp Ala Asp Leu Gly Ser Asn Gly Lys Val
1856 465                 470                     475                 480
1858 Ser Tyr Arg Ile Lys Asp Ser Pro Val Ser His Leu Val Ile Ile Asp
1859             485                 490                     495
1861 Phe Glu Thr Gly Glu Val Thr Ala Gln Arg Ser Leu Asp Tyr Glu Gln
1862             500                 505                 510
1864 Met Ala Gly Phe Glu Phe Gln Val Ile Ala Glu Asp Arg Gly Gln Pro
1865             515                 520                 525
1867 Gln Leu Ala Ser Ser Ile Ser Val Trp Val Ser Leu Leu Asp Ala Asn
1868         530                 535                 540
1870 Asp Asn Ala Pro Glu Val Ile Gln Pro Val Leu Ser Glu Gly Lys Ala
1871 545                 550                 555                 560
1873 Thr Leu Ser Val Leu Val Asn Ala Ser Thr Gly His Leu Leu Leu Pro
1874             565                 570                 575
1876 Ile Glu Asn Pro Ser Gly Met Asp Pro Ala Gly Thr Gly Ile Pro Pro
1877         580                     585                 590
1879 Lys Ala Thr His Ser Pro Trp Ser Phe Leu Leu Leu Thr Ile Val Ala
1880         595                 600                 605
1882 Arg Asp Ala Asp Ser Gly Ala Asn Gly Glu Leu Phe Tyr Ser Ile Gln
1883 610                     615                 620
1885 Ser Gly Asn Asp Ala His Leu Phe Phe Leu Ser Pro Ser Leu Gly Gln
1886 625                     630                 635                 640
1888 Leu Phe Ile Asn Val Thr Asn Ala Ser Ser Leu Ile Gly Ser Gln Trp
1889                 645                 650                 655
1891 Asp Leu Gly Ile Val Val Glu Asp Gln Gly Ser Pro Ser Leu Gln Thr
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
1892                660               665               670
1894 Gln Val Ser Leu Lys Val Val Phe Val Thr Ser Val Asp His Leu Arg
1895         675               680               685
1897 Asp Ser Ala His Glu Pro Gly Val Leu Ser Thr Pro Ala Leu Ala Leu
1898     690               695               700
1900 Ile Cys Leu Ala Val Leu Leu Ala Ile Phe Gly Leu Leu Leu Ala Leu
1901 705               710               715               720
1903 Phe Val Ser Ile Cys Arg Thr Glu Arg Lys Asp Asn Arg Ala Tyr Asn
1904                 725               730               735
1906 Cys Arg Glu Ala Glu Ser Ser Tyr Arg His Gln Pro Lys Arg Pro Gln
1907             740               745               750
1909 Lys His Ile Gln Lys Ala Asp Ile His Leu Val Pro Val Leu Arg Ala
1910         755               760               765
1912 His Glu Asn Glu Thr Asp Glu Val Arg Pro Ser His Lys Asp Thr Ser
1913     770               775               780
1915 Lys Glu Thr Leu Met Glu Ala Gly Trp Asp Ser Cys Leu Glu Ala Pro
1916 785               790               795               800
1918 Phe His Leu Thr Pro Thr Leu Tyr Arg Thr Leu Arg Asn Gln Gly Asn
1919             805               810               815
1921 Gln Gly Glu Leu Ala Glu Ser Gln Glu Val Leu Gln Asp Thr Phe Asn
1922             820               825               830
1924 Phe Leu Phe Asn His Pro Arg Gln Arg Asn Ala Ser Arg Glu Asn Leu
1925         835               840               845
1927 Asn Leu Pro Glu Ser Pro Pro Ala Val Arg Gln Pro Leu Leu Arg Pro
1928     850               855               860
1930 Leu Lys Val Pro Gly Ser Pro Ile Ala Arg Ala Thr Gly Asp Gln Asp
1931 865               870               875               880
1933 Lys Glu Glu Ala Pro Gln Ser Pro Pro Ala Ser Ser Ala Thr Leu Arg
1934             885               890               895
1936 Arg Gln Arg Asn Phe Asn Gly Lys Val Ser Pro Arg Gly Glu Ser Gly
1937             900               905               910
1939 Pro His Gln Ile Leu Arg Ser Leu Val Arg Leu Ser Val Ala Ala Phe
1940         915               920               925
1942 Ala Glu Arg Asn Pro Val Glu Glu Pro Ala Gly Asp Ser Pro Pro Val
1943     930               935               940
1945 Gln Gln Ile Ser Gln Leu Leu Ser Leu Leu His Gln Gly Gln Phe Gln
1946 945               950               955               960
1948 Pro Lys Pro Asn His Arg Gly Asn Lys Tyr Leu Ala Lys Pro Gly Gly
1949             965               970               975
1951 Ser Ser Arg Gly Thr Ile Pro Asp Thr Glu Gly Leu Val Gly Leu Lys
1952             980               985               990
1954 Pro Ser Gly Gln Ala Glu Pro Asp Leu Glu Glu Gly Pro Pro Ser Pro
1955             995               1000              1005
1957 Leu Ser Ser Leu Leu Asp Pro Asn Thr Gly Leu Ala Leu Asp Lys Leu
1958     1010              1015              1020
1960 Ser Pro Pro Asp Pro Ala Trp Met Ala Arg Leu Ser Leu Pro Leu Thr
1961 1025              1030              1035              1040
1963 Ser Glu Glu Pro Arg Thr Phe Gln Thr Phe Gly Lys Thr Val Gly Pro
1964             1045              1050              1055
```

RAW SEQUENCE LISTING   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:32

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
  1966 Gly Pro Glu Leu Ser Pro Thr Gly Thr Arg Leu Ala Ser Thr Phe Val
  1967           1060              1065              1070
  1969 Ser Glu Met Ser Ser Leu Leu Glu Met Leu Leu Gly Gln His Thr Val
  1970      1075              1080              1085
  1972 Pro Val Glu Ala Ala Ser Ala Ala Leu Arg Arg Leu Ser Val Cys Gly
  1973    1090              1095              1100
  1975 Arg Thr Leu Ser Leu Asp Leu Ala Thr Ser Gly Ala Ser Ala Ser Glu
  1976 1105              1110              1115              1120
  1978 Ala Gln Gly Arg Lys Lys Ala Ala Glu Ser Arg Leu Gly Cys Gly
E--> 1979           1125              1130              1135
```

Use of n and/or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.

VERIFICATION SUMMARY   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:35

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

L:20 M:270 C: Current Application Number differs, Replaced Current Application Number
L:21 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:391 M:252 E: No. of Seq. differs, <211>LENGTH:Input:1151 Found:911 SEQ:3
L:859 M:283 W: Missing Blank Line separator, <400> field identifier
L:860 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (9) SEQUENCE:
L:864 M:283 W: Missing Blank Line separator, <400> field identifier
L:865 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (10) SEQUENCE:
L:869 M:283 W: Missing Blank Line separator, <400> field identifier
L:870 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (11) SEQUENCE:
L:874 M:283 W: Missing Blank Line separator, <400> field identifier
L:875 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (12) SEQUENCE:
L:879 M:283 W: Missing Blank Line separator, <400> field identifier
L:880 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (13) SEQUENCE:
L:884 M:283 W: Missing Blank Line separator, <400> field identifier
L:885 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (14) SEQUENCE:
L:889 M:283 W: Missing Blank Line separator, <400> field identifier
L:890 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (15) SEQUENCE:
L:894 M:283 W: Missing Blank Line separator, <400> field identifier
L:895 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (16) SEQUENCE:
L:899 M:283 W: Missing Blank Line separator, <400> field identifier
L:900 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (17) SEQUENCE:
L:904 M:283 W: Missing Blank Line separator, <400> field identifier
L:905 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (18) SEQUENCE:
L:909 M:283 W: Missing Blank Line separator, <400> field identifier
L:910 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (19) SEQUENCE:
L:914 M:283 W: Missing Blank Line separator, <400> field identifier
L:915 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (20) SEQUENCE:
L:919 M:283 W: Missing Blank Line separator, <400> field identifier
L:920 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (21) SEQUENCE:
L:924 M:283 W: Missing Blank Line separator, <400> field identifier
L:925 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (22) SEQUENCE:
L:929 M:283 W: Missing Blank Line separator, <400> field identifier
L:930 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (23) SEQUENCE:
L:934 M:283 W: Missing Blank Line separator, <400> field identifier
L:935 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (24) SEQUENCE:
L:939 M:283 W: Missing Blank Line separator, <400> field identifier
L:940 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (25) SEQUENCE:
L:944 M:283 W: Missing Blank Line separator, <400> field identifier
L:945 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (26) SEQUENCE:
L:949 M:283 W: Missing Blank Line separator, <400> field identifier
L:950 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (27) SEQUENCE:
L:954 M:283 W: Missing Blank Line separator, <400> field identifier
L:955 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (28) SEQUENCE:
L:959 M:283 W: Missing Blank Line separator, <400> field identifier
L:960 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (29) SEQUENCE:
L:964 M:283 W: Missing Blank Line separator, <400> field identifier
L:965 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (30) SEQUENCE:
L:1348 M:283 W: Missing Blank Line separator, <400> field identifier

VERIFICATION SUMMARY   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:35

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
L:1349 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (34) SEQUENCE:
L:1570 M:283 W: Missing Blank Line separator, <400> field identifier
L:1571 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (36) SEQUENCE:
L:1575 M:283 W: Missing Blank Line separator, <400> field identifier
L:1576 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (37) SEQUENCE:
L:1640 M:252 E: No. of Seq. differs, <211>LENGTH:Input:423 Found:295 SEQ:38
L:1644 M:283 W: Missing Blank Line separator, <400> field identifier
L:1645 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (39) SEQUENCE:
L:1979 M:252 E: No. of Seq. differs, <211>LENGTH:Input:1183 Found:1135 SEQ:42
L:1983 M:283 W: Missing Blank Line separator, <400> field identifier
L:1984 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (43) SEQUENCE:
L:1988 M:283 W: Missing Blank Line separator, <400> field identifier
L:1989 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (44) SEQUENCE:
L:1993 M:283 W: Missing Blank Line separator, <400> field identifier
L:1994 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (45) SEQUENCE:
L:1998 M:283 W: Missing Blank Line separator, <400> field identifier
L:1999 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (46) SEQUENCE:
L:2003 M:283 W: Missing Blank Line separator, <400> field identifier
L:2004 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (47) SEQUENCE:
L:2008 M:283 W: Missing Blank Line separator, <400> field identifier
L:2009 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (48) SEQUENCE:
L:2013 M:283 W: Missing Blank Line separator, <400> field identifier
L:2014 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (49) SEQUENCE:
L:2018 M:283 W: Missing Blank Line separator, <400> field identifier
L:2019 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (50) SEQUENCE:
L:2428 M:283 W: Missing Blank Line separator, <400> field identifier
L:2429 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (62) SEQUENCE:
L:2433 M:283 W: Missing Blank Line separator, <400> field identifier
L:2434 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (63) SEQUENCE:
L:2438 M:283 W: Missing Blank Line separator, <400> field identifier
L:2439 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (64) SEQUENCE:
L:2443 M:283 W: Missing Blank Line separator, <400> field identifier
L:2444 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (65) SEQUENCE:
L:2448 M:283 W: Missing Blank Line separator, <400> field identifier
L:2449 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (66) SEQUENCE:
L:2453 M:283 W: Missing Blank Line separator, <400> field identifier
L:2454 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (67) SEQUENCE:
L:2458 M:283 W: Missing Blank Line separator, <400> field identifier
L:2459 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (68) SEQUENCE:
L:2463 M:283 W: Missing Blank Line separator, <400> field identifier
L:2464 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (69) SEQUENCE:
L:2468 M:283 W: Missing Blank Line separator, <400> field identifier
L:2469 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (70) SEQUENCE:
L:3032 M:283 W: Missing Blank Line separator, <400> field identifier
L:3033 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (79) SEQUENCE:
L:3037 M:283 W: Missing Blank Line separator, <400> field identifier
L:3038 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (80) SEQUENCE:
L:3113 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:81
L:3113 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
```

VERIFICATION SUMMARY   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:35

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
L:3114 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:81
L:3114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3283 M:283 W: Missing Blank Line separator, <400> field identifier
L:3284 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (87) SEQUENCE:
L:3331 M:283 W: Missing Blank Line separator, <400> field identifier
L:3332 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (89) SEQUENCE:
L:3336 M:283 W: Missing Blank Line separator, <400> field identifier
L:3337 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (90) SEQUENCE:
L:3411 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:91
L:3411 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:91
L:3412 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:91
L:3412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:91
L:3604 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:96
L:3604 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:96
L:3605 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:96
L:3605 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:96
L:3790 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:101
L:3790 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:101
L:3791 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:101
L:3791 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:101
L:3972 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:106
L:3972 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:106
L:3973 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:106
L:3973 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:106
L:4150 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:111
L:4150 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111
L:4151 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:111
L:4151 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111
L:4253 M:283 W: Missing Blank Line separator, <400> field identifier
L:4254 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (116) SEQUENCE:
L:4258 M:283 W: Missing Blank Line separator, <400> field identifier
L:4259 M:300 W: (50) Intentionally skipped Sequence, : Sequence Id (117) SEQUENCE:
L:9840 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:324
L:9840 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:324
L:11213 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:343
L:11213 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:343
L:16904 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:450
L:16904 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:450
L:16904 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:450
L:16951 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:451
L:16951 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:451
L:16951 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:451
L:16983 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:452
L:16983 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:452
L:16983 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:452
L:17009 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:453
L:17009 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:453
L:17009 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:453
L:17036 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:454
```

VERIFICATION SUMMARY   DATE: 10/04/2001
PATENT APPLICATION: US/09/759,130A   TIME: 13:00:35

Input Set : A:\10147-61.app
Output Set: N:\CRF3\10042001\I759130A.raw

```
L:17036 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:454
L:17036 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:454
L:17039 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:454
L:17039 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:454
L:17039 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:454
L:17042 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:454
L:17042 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:454
L:17042 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:454
L:17062 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:455
L:17062 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:455
L:17062 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:455
L:17083 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:456
L:17083 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:456
L:17083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:456
L:17086 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:456
L:17086 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:456
L:17086 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:456
L:17089 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:456
L:17089 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:456
L:17089 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:456
L:17124 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:457
L:17124 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:457
L:17124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:457
L:17127 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:457
L:17127 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:457
L:17127 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:457
```

/